Restricted accessResearch articleFirst published online 2016-11
Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif,Vpr,and Vpu That Are Under Subsequent Immune Pressure During Early Infection
Viral variants that predominate during early infection may exhibit constrained diversity compared with those found during chronic infection and could contain amino acid signature patterns that may enhance transmission, establish productive infection, and influence early events that modulate the infection course. We compared amino acid distributions in 17 patients recently infected with HIV-1C with patients with chronic infection. We found significantly lower entropy in inferred transmitted/founder (t/f) compared with chronic viruses and identified signature patterns in Vif and Vpr from inferred t/f viruses. We investigated sequence evolution longitudinally up to 500 days postseroconversion and compared the impact of selected substitutions on predicted human leukocyte antigen (HLA) binding affinities of published and predicted cytotoxic T-lymphocyte epitopes. Polymorphisms in Vif and Vpr during early infection occurred more frequently at epitope-HLA anchor residues and significantly decreased predicted epitope-HLA binding. Transmission-associated sequence signatures may have implications for novel strategies to prevent HIV-1 transmission.
Get full access to this article
View all access options for this article.
References
1.
AbrahamsMR, AndersonJA, GiorgiEE, SeoigheC, MlisanaK, PingLH, AthreyaGS, TreurnichtFK, KeeleBF, WoodN, Salazar-GonzalezJF, BhattacharyaT, ChuH, HoffmanI, GalvinS, MapanjeC, KazembeP, ThebusR, FiscusS, HideW, CohenMS, KarimSA, HaynesBF, ShawGM, HahnBH, KorberBT, SwanstromR, WilliamsonC: Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol, 2009; 83:3556–3567.
FischerW, GanusovVV, GiorgiEE, HraberPT, KeeleBF, LeitnerT, HanCS, GleasnerCD, GreenL, LoCC, NagA, WallstromTC, WangS, McMichaelAJ, HaynesBF, HahnBH, PerelsonAS, BorrowP, ShawGM, BhattacharyaT, KorberBT: Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One, 2010; 5:e12303.
4.
KeeleBF, GiorgiEE, Salazar-GonzalezJF, DeckerJM, PhamKT, SalazarMG, SunC, GraysonT, WangS, LiH, WeiX, JiangC, KirchherrJL, GaoF, AndersonJA, PingLH, SwanstromR, TomarasGD, BlattnerWA, GoepfertPA, KilbyJM, SaagMS, DelwartEL, BuschMP, CohenMS, MontefioriDC, HaynesBF, GaschenB, AthreyaGS, LeeHY, WoodN, SeoigheC, PerelsonAS, BhattacharyaT, KorberBT, HahnBH, ShawGM: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A, 2008; 105:7552–7557.
5.
NovitskyV, WangR, MargolinL, BacaJ, RossenkhanR, MoyoS, van WidenfeltE, EssexM: Transmission of single and multiple viral variants in primary HIV-1 subtype C infection. PLoS One, 2011; 6:e16714.
6.
SagarM, LaeyendeckerO, LeeS, GamielJ, WawerMJ, GrayRH, SerwaddaD, SewankamboNK, ShepherdJC, TomaJ, HuangW, QuinnTC: Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis, 2009; 199:580–589.
MotaTM, MurrayJM, CenterRJ, PurcellDF, McCawJM: Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission. Retrovirology, 2012; 9:54.
9.
ChohanB, LangD, SagarM, KorberB, LavreysL, RichardsonB, OverbaughJ: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol, 2005; 79:6528–6531.
10.
Fenton-MayAE, DibbenO, EmmerichT, DingH, PfafferottK, Aasa-ChapmanMM, PellegrinoP, WilliamsI, CohenMS, GaoF, ShawGM, HahnBH, OchsenbauerC, KappesJC, BorrowP: Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology, 2013; 10:146.
11.
HerbeckJT, RollandM, LiuY, McLaughlinS, McNevinJ, ZhaoH, WongK, StoddardJN, RaugiD, SorensenS, GenowatiI, BirdittB, McKayA, DiemK, MaustBS, DengW, CollierAC, SteklerJD, McElrathMJ, MullinsJI: Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol, 2011; 85:7523–7534.
12.
WalkerBD, ChakrabartiS, MossB, ParadisTJ, FlynnT, DurnoAG, BlumbergRS, KaplanJC, HirschMS, SchooleyRT: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature, 1987; 328:345–348.
13.
BrummeZL, BrummeCJ, CarlsonJ, StreeckH, JohnM, EichbaumQ, BlockBL, BakerB, KadieC, MarkowitzM, JessenH, KelleherAD, RosenbergE, KaldorJ, YukiY, CarringtonM, AllenTM, MallalS, AltfeldM, HeckermanD, WalkerBD: Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol, 2008; 82:9216–9227.
14.
BrummeZL, BrummeCJ, HeckermanD, KorberBT, DanielsM, CarlsonJ, KadieC, BhattacharyaT, ChuiC, SzingerJ, MoT, HoggRS, MontanerJS, FrahmN, BranderC, WalkerBD, HarriganPR: Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog, 2007; 3:e94.
15.
KelleherAD, BoothBLJr., SewellAK, OxeniusA, CerundoloV, McMichaelAJ, PhillipsRE, PriceDA: Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes. AIDS Res Hum Retroviruses, 2001; 17:1063–1066.
16.
RousseauCM, DanielsMG, CarlsonJM, KadieC, CrawfordH, PrendergastA, MatthewsP, PayneR, RollandM, RaugiDN, MaustBS, LearnGH, NickleDC, CoovadiaH, Ndung'uT, FrahmN, BranderC, WalkerBD, GoulderPJ, BhattacharyaT, HeckermanDE, KorberBT, MullinsJI: HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: Immune escape and viral load. J Virol, 2008; 82:6434–6446.
TreurnichtFK, SeoigheC, MartinDP, WoodN, AbrahamsMR, Rosa DdeA, BredellH, WoodmanZ, HideW, MlisanaK, KarimSA, GrayCM, WilliamsonC: Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure. Virology, 2009; 396:213–225.
19.
HennMR, BoutwellCL, CharleboisP, LennonNJ, PowerKA, MacalaladAR, BerlinAM, MalboeufCM, RyanEM, GnerreS, ZodyMC, ErlichRL, GreenLM, BericalA, WangY, CasaliM, StreeckH, BloomAK, DudekT, TullyD, NewmanR, AxtenKL, GladdenAD, BattisL, KemperM, ZengQ, SheaTP, GujjaS, ZedlackC, GasserO, BranderC, HessC, GunthardHF, BrummeZL, BrummeCJ, BaznerS, RychertJ, TinsleyJP, MayerKH, RosenbergE, PereyraF, LevinJZ, YoungSK, JessenH, AltfeldM, BirrenBW, WalkerBD, AllenTM: Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog, 2012; 8:e1002529.
20.
JosephSB, SwanstromR, KashubaAD, CohenMS: Bottlenecks in HIV-1 transmission: Insights from the study of founder viruses. Nat Rev Microbiol, 2015; 13:414–425.
21.
NovitskyV, LagakosS, HerzigM, BonneyC, KebaabetsweL, RossenkhanR, NkweD, MargolinL, MusondaR, MoyoS, WoldegabrielE, van WidenfeltE, MakhemaJ, EssexM: Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology, 2009; 383:47–59.
22.
NovitskyV, WoldegabrielE, WesterC, McDonaldE, RossenkhanR, KetunutiM, MakhemaJ, SeageGR3rd, EssexM: Identification of primary HIV-1C infection in Botswana. AIDS care, 2008; 20:806–811.
23.
FiebigEW, WrightDJ, RawalBD, GarrettPE, SchumacherRT, PeddadaL, HeldebrantC, SmithR, ConradA, KleinmanSH, BuschMP: Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS, 2003; 17:1871–1879.
24.
NovitskyV, WangR, KebaabetsweL, GreenwaldJ, RossenkhanR, MoyoS, MusondaR, WoldegabrielE, LagakosS, EssexM: Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. J Acquir Immune Defic Syndr, 2009; 52:265–272.
25.
RossenkhanR, NovitskyV, SebunyaTK, MusondaR, GasheBA, EssexM: Viral diversity and diversification of major non-structural genes vif, vpr, vpu, tat exon 1 and rev exon 1 during primary HIV-1 subtype C infection. PLoS One, 2011; 7:e35491.
26.
LiuSL, RodrigoAG, ShankarappaR, LearnGH, HsuL, DavidovO, ZhaoLP, MullinsJI: HIV quasispecies and resampling. Science, 1996; 273:415–416.
27.
DengW, MaustBS, NickleDC, LearnGH, LiuY, HeathL, Kosakovsky PondSL, MullinsJI: DIVEIN: A web server to analyze phylogenies, sequence divergence, diversity, and informative sites. Biotechniques, 2010; 48:405–408.
28.
GuindonS, GascuelO: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol, 2003; 52:696–704.
29.
TamuraK, PetersonD, PetersonN, StecherG, NeiM, KumarS: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol, 2011; 28:2731–2739.
30.
KorberBT, KunstmanKJ, PattersonBK, FurtadoM, McEvillyMM, LevyR, WolinskySM: Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: Evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol, 1994; 68:7467–7481.
31.
BenjaminiY, HochbergY: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B, 1995; 57:289–300.
32.
R Core Team. R: A language and environment for statistical computing [computer program]. Vienna: R Foundation for Statistical Computing; 2015. Available at: www.R-project.org, accessed June6, 2016.
33.
NovitskyV, WangR, MargolinL, BacaJ, KebaabetsweL, RossenkhanR, BonneyC, HerzigM, NkweD, MoyoS, MusondaR, WoldegabrielE, van WidenfeltE, MakhemaJ, LagakosS, EssexM: Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection. PLoS One, 2009; 4:e7727.
RasmussenM, HarndahlM, StryhnA, BouchermaR, NielsenLL, LemonnierFA, NielsenM, BuusS: Uncovering the peptide-binding specificities of HLA-C: A general strategy to determine the specificity of any MHC class I molecule. J Immunol, 2014; 193:4790–4802.
36.
BellCM, ConnellBJ, CapovillaA, VenterWD, StevensWS, PapathanasopoulosMA: Molecular characterization of the HIV type 1 subtype C accessory genes vif, vpr, and vpu. AIDS Res Hum Retroviruses, 2007; 23:322–330.
37.
HasanZ, CarlsonJM, GatanagaH, LeAQ, BrummeCJ, OkaS, BrummeZL, UenoT: Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu. Biochem Biophys Res Commun, 2012; 421:291–295.
38.
PickeringS, HueS, KimEY, ReddyS, WolinskySM, NeilSJ: Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog, 2014; 10:e1003895.
39.
SiwkaW, SchwinnA, BaczkoK, PardowitzI, MhaluF, ShaoJ, RethwilmA, ter MeulenV: vpu and env sequence variability of HIV-1 isolates from Tanzania. AIDS Res Hum Retroviruses, 1994; 10:1753–1754.
40.
KorberB, MyersG: Signature pattern analysis: A method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses, 1992; 8:1549–1560.
41.
KiepielaP, NgumbelaK, ThobakgaleC, RamduthD, HoneyborneI, MoodleyE, ReddyS, de PierresC, MncubeZ, MkhwanaziN, BishopK, van der StokM, NairK, KhanN, CrawfordH, PayneR, LeslieA, PradoJ, PrendergastA, FraterJ, McCarthyN, BranderC, LearnGH, NickleD, RousseauC, CoovadiaH, MullinsJI, HeckermanD, WalkerBD, GoulderP: CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med, 2007; 13:46–53.
42.
ConticelloSG, HarrisRS, NeubergerMS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol, 2003; 13:2009–2013.
MalimMH: Natural resistance to HIV infection: The Vif-APOBEC interaction. C R Biol, 2006; 329:871–875.
45.
MarianiR, ChenD, SchrofelbauerB, NavarroF, KonigR, BollmanB, MunkC, Nymark-McMahonH, LandauNR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell, 2003; 114:21–31.
46.
RomaniB, EngelbrechtS, GlashoffRH: Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif. Arch Virol, 2009; 154:1579–1588.
47.
SheehyAM, GaddisNC, ChoiJD, MalimMH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 2002; 418:646–650.
48.
SheehyAM, GaddisNC, MalimMH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med, 2003; 9:1404–1407.
49.
YangB, GaoL, LiL, LuZ, FanX, PatelCA, PomerantzRJ, DuBoisGC, ZhangH: Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem, 2003; 278:6596–6602.
50.
FujitaM, AkariH, SakuraiA, YoshidaA, ChibaT, TanakaK, StrebelK, AdachiA: Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect, 2004; 6:791–798.
51.
NovitskyV, SmithUR, GilbertP, McLaneMF, ChigwedereP, WilliamsonC, Ndung'uT, KleinI, ChangSY, PeterT, ThiorI, FoleyBT, GaolekweS, RybakN, GaseitsiweS, VannbergF, MarlinkR, LeeTH, EssexM: Human immunodeficiency virus type 1 subtype C molecular phylogeny: Consensus sequence for an AIDS vaccine design?. J Virol, 2002; 76:5435–5451.
52.
JacobsGB, NistalM, LatenA, van RensburgEJ, RethwilmA, PreiserW, BodemJ, EngelbrechtS: Molecular analysis of HIV type 1 vif sequences from Cape Town, South Africa. AIDS Res Hum Retroviruses, 2008; 24:991–994.
53.
WielandU, HartmannJ, SuhrH, SalzbergerB, EggersHJ, KuhnJE: In vivo genetic variability of the HIV-1 vif gene. Virology, 1994; 203:43–51.
54.
ScribaTJ, TreurnichtFK, ZeierM, EngelbrechtS, van RensburgEJ: Characterization and phylogenetic analysis of South African HIV-1 subtype C accessory genes. AIDS Res Hum Retroviruses, 2001; 17:775–781.
55.
Le RouzicE, BenichouS: The Vpr protein from HIV-1: Distinct roles along the viral life cycle. Retrovirology, 2005; 2:11.
56.
RomaniB, GlashoffR, EngelbrechtS: Molecular and phylogenetic analysis of HIV type 1 vpr sequences of South African strains. AIDS Res Hum Retroviruses, 2009; 25:357–362.
57.
JacototE, RavagnanL, LoefflerM, FerriKF, VieiraHL, ZamzamiN, CostantiniP, DruillennecS, HoebekeJ, BriandJP, IrinopoulouT, DaugasE, SusinSA, CointeD, XieZH, ReedJC, RoquesBP, KroemerG: The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med, 2000; 191:33–46.
58.
LumJJ, CohenOJ, NieZ, WeaverJG, GomezTS, YaoXJ, LynchD, PilonAA, HawleyN, KimJE, ChenZ, MontpetitM, Sanchez-DardonJ, CohenEA, BadleyAD: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest, 2003; 111:1547–1554.
59.
TungaturthiPK, SawayaBE, AyyavooV, MuraliR, SrinivasanA: HIV-1 Vpr: Genetic diversity and functional features from the perspective of structure. DNA Cell Biol, 2004; 23:207–222.
60.
JacquotG, Le RouzicE, DavidA, MazzoliniJ, BouchetJ, BouazizS, NiedergangF, PancinoG, BenichouS: Localization of HIV-1 Vpr to the nuclear envelope: Impact on Vpr functions and virus replication in macrophages. Retrovirology, 2007; 4:84.
61.
KamataM, Nitahara-KasaharaY, MiyamotoY, YonedaY, AidaY: Importin-alpha promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr. J Virol, 2005; 79:3557–3564.
62.
KoganM, RappaportJ: HIV-1 accessory protein Vpr: Relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology, 2011; 8:25.
63.
SawayaBE, KhaliliK, GordonJ, SrinivasanA, RichardsonM, RappaportJ, AminiS: Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73. J Virol, 2000; 74:4877–4881.
64.
Besnard-GuerinC, BelaidouniN, LassotI, SegeralE, JobartA, MarchalC, BenarousR: HIV-1 Vpu sequesters beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCFbetaTrCP substrates. J Biol Chem, 2004; 279:788–795.
65.
MlcochovaP, ApoloniaL, KlugeSF, SridharanA, KirchhoffF, MalimMH, SauterD, GuptaRK: Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. Virology, 2015; 482:72–78.
66.
GoonetillekeN, LiuMK, Salazar-GonzalezJF, FerrariG, GiorgiE, GanusovVV, KeeleBF, LearnGH, TurnbullEL, SalazarMG, WeinholdKJ, MooreS, LetvinN, HaynesBF, CohenMS, HraberP, BhattacharyaT, BorrowP, PerelsonAS, HahnBH, ShawGM, KorberBT, McMichaelAJ: The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med, 2009; 206:1253–1272.
67.
BazhanSI, KarpenkoLI, IlyichevaTN, BelavinPA, SereginSV, DanilyukNK, AntonetsDV, IlyichevAA: Rational design based synthetic polyepitope DNA vaccine for eliciting HIV-specific CD8+ T cell responses. Mol Immunol, 2007; 47:1507–1515.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
